Abstract：
:We conducted a study in order to characterize changes after withdrawal of androgen ablation (AA) for prostate cancer. AA was withdrawn in 38 Japanese patients with prostate cancer who had undergone this therapy for various periods. Patients were stratified into those who had undergone AA for less than 24 months (Group 1, n=12) and those with longer periods of AA (Group 2, n=26). Serial changes in hormones and prostate-specific antigen (PSA) were prospectively monitored following cessation of AA. The median durations of AA in the two groups were 8.5 and 54.5 months, respectively. Levels of total testosterone (T), luteinizing hormone and PSA increased significantly with time. At the end of 2 y, 30/38 patients (78.9%) had T levels above 50 ng/dl and 19/38 (50%) had levels above 320 ng/dl. Patients in Group 2 required significantly longer duration for T recovery. Complete T recovery is not always accompanied by rising PSA. Recovery of T levels is often slow following cessation of prolonged AA. Expression of PSA after AA is often variable and unpredictable. Thus, interpretation of outcomes in clinical trials incorporating AA needs caution and careful consideration.
journal_name
Prostate Cancer Prostatic Disjournal_title
Prostate cancer and prostatic diseasesauthors
Egawa S,Okusa H,Matsumoto K,Suyama K,Baba Sdoi
10.1038/sj.pcan.4500675subject
Has Abstractpub_date
2003-01-01 00:00:00pages
245-9issue
3eissn
1365-7852issn
1476-5608pii
4500675journal_volume
6pub_type
临床试验,杂志文章abstract：:Side effects accompanying androgen deprivation therapy (ADT), including sarcopenia, loss of bone mass and reduction in muscle strength, can compromise physical function, particularly in older patients. Exercise, specifically resistance training, may be an effective and cost-efficient strategy to limit or even reverse ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/sj.pcan.4500975
更新日期：2007-01-01 00:00:00
abstract：:This literature review discusses the theoretical background of 5alpha-reductase inhibitor (5ARI) treatment and the resulting clinical implications. A Medline-based search for peer-reviewed articles addressing 5ARIs, benign prostatic hyperplasia and prostate cancer was performed. The 5ARIs Finasteride and Dutasteride, ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/pcan.2008.56
更新日期：2009-01-01 00:00:00
abstract：:Randomized data from SWOG 8794 and EORTC 22911 confirm the benefit of post-operative radiation therapy (RT) for selected patients with pT3 prostate cancer (CaP) after radical prostatectomy (RP). However, data regarding the potential benefit of RT for patients post-RP with positive lymph node (+LN) involvement are limi...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500940
更新日期：2007-01-01 00:00:00
abstract：BACKGROUND:To compare prostate cancer detection rates between transrectal ultrasound (TRUS) prostate biopsy and transperineal template prostate biopsy (TPTPB) in biopsy naïve men. TRUS biopsy is still regarded as gold standard for prostate cancer diagnosis. TPTPB has been shown to improve prostate cancer detection in m...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2014.4
更新日期：2014-06-01 00:00:00
abstract：BACKGROUND:The value of radical prostatectomy (RP) as an approach for very high-risk prostate cancer (PCa) patients is controversial. To examine the risk of 10-year cancer-specific mortality (CSM) and other-cause mortality (OCM) according to clinical and pathological characteristics of very high-risk cT3b/4 PCa patient...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,多中心研究
doi：10.1038/pcan.2014.41
更新日期：2015-03-01 00:00:00
abstract：:'Insignificant' prostate cancer is defined as disease of virulence insufficient to threaten survival. In this review, which describes nine articles and two abstracts discussing almost 800 cases, we discuss the correlation of such 'insignificant' biopsy findings in the context of subsequent radical prostatectomy data. ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/sj.pcan.4500963
更新日期：2007-01-01 00:00:00
abstract：BACKGROUND:Several treatment options for clinically localized prostate cancer currently exist under the established guidelines. We aim to assess nationally representative trends in treatment over time and determine potential geographic variation using two large national claims registries. METHODS:Men with prostate can...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2015.3
更新日期：2015-06-01 00:00:00
abstract：:The purpose of the present study was to perform a BPH risk factor analysis in men, relating the prostate gland volume to components of the metabolic syndrome and to identify clues to the etiology of BPH. Our material comprised a consecutive series of 158 patients with lower urinary tract symptoms with or without manif...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500221
更新日期：1998-03-01 00:00:00
abstract：:The Insulin-like Growth Factor (IGF) network in prostate tissue represents a key element in normal and tumour growth. It can provide us with new markers for prognosis or diagnosis and targets for treatment of prostate diseases. This short review introduces the IGF network in general and in the prostate gland, summaris...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500295
更新日期：1999-03-01 00:00:00
abstract：:An increased molecular understanding of localized prostate cancer and the improved ability for molecular testing of pathologic tissue has led to the development of multiple clinical assays. Here we review the relevant molecular biology of localized prostate cancer, currently available tissue-based tests and describe w...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/pcan.2015.31
更新日期：2016-03-01 00:00:00
abstract：:We present a critical review of the recent literature and discuss the development and prospective view of the evaluations of transrectal ultrasound with regard to prostate malignancy. We illustrate this with personal experiences. Material and Methods: Based on a critical evaluation of clinical data we address the appa...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500326
更新日期：1999-12-01 00:00:00
abstract：:Vascular endothelial growth factor (VEGF) is a heparin-binding polypeptide growth factor. It is a potent mitogen for endothelial cells. Immunohistochemical localisation of VEGF was performed on 25 moderate to poorly differentiated stage T4 M+ prostate cancer specimens and 30 benign prostatic hyperplasia (BPH) specimen...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500575
更新日期：2002-01-01 00:00:00
abstract：:Prostate cancer appears to result from complex interactions among genetic, endocrine and environmental factors. Identification of risk factors for development and progression of prostate cancer is needed. This will allow researchers to design strategies to reduce the morbidity and mortality from this cancer and to ide...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500471
更新日期：2000-12-01 00:00:00
abstract：:The purpose of this study was to evaluate the relationship of baseline body mass index (BMI) and serum testosterone level with prostate cancer outcomes in men with castration-resistant metastatic prostate cancer (CRPC). BMI and testosterone levels were evaluated for their ability to predict overall survival (OS) and p...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2008.36
更新日期：2009-01-01 00:00:00
abstract：:Rectum and bladder are the crucial organs at risk for curative radiation therapy of localized prostate cancer. We analyzed the incidence, profile and time course of late rectal radiation toxicity. A total of 320 patients with T1-3 prostate cancer were treated with three-dimensional conformal radiation therapy (3D-CRT)...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2009.56
更新日期：2010-06-01 00:00:00
abstract：BACKGROUND:Surgery and radiation-based therapies are standard management options for men with clinically localized high-risk prostate cancer (PCa). Contemporary patterns of care are unknown. We hypothesize the use of surgery has steadily increased in more recent years. METHODS:Using the National Cancer Data Base for 2...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2017.5
更新日期：2017-09-01 00:00:00
abstract：BACKGROUND:Treatment of high-risk prostate cancer has evolved considerably over the past two decades, yet patients with very-high-risk features may still experience poor outcome despite aggressive therapy. We review the contemporary literature focusing on current definitions, role of modern imaging and treatment altern...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/pcan.2016.40
更新日期：2016-12-01 00:00:00
abstract：BACKGROUND:Prostate cancer is the most common cancer in American men that ranges from low risk states amenable to active surveillance to high-risk states that can be lethal especially if untreated. There is a critical need to develop relatively non-invasive and clinically useful methods for screening, detection, progno...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/s41391-019-0127-4
更新日期：2019-09-01 00:00:00
abstract：BACKGROUND:Approximately 29-38% of all positive surgical margins (PSMs) at radical prostatectomy (RP) involve the apex. The prognostic significance of apical PSM remains unclear. We therefore compared the long-term oncologic outcomes of men with apical PSMs to those with negative PSMs, apical and other PSMs, and other ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2016.45
更新日期：2016-12-01 00:00:00
abstract：:With growing number of older adults in the United States and complexity of issues related to Medicare and other insurances more research is needed to evaluate an effectiveness of the different insurance types in prevention, screening and treatment of cancer. With prostate cancer being highly prevalent disease in older...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4501015
更新日期：2008-01-01 00:00:00
abstract：:As high grade PIN is commonly associated with concomitant cancer, current literature recommends re-biopsy of patients with high grade PIN. This paper describes the prevalence of high grade prostatic intra-epithelial neoplasia (PIN) from three independent clinical settings, reported by a single pathologist (MCP). High ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500210
更新日期：1997-12-01 00:00:00
abstract：:Prostate cancer patients' management demands prioritization, adjustments, and a tailored approach during the unprecedented SARS-CoV-2 pandemic. Benefit of care from treatment must be carefully weighed against the potential of infection and morbidity from COVID-19. Furthermore, urologists need to be cognizant of their ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/s41391-020-0258-7
更新日期：2020-09-01 00:00:00
abstract：:Chronic fatigue (CF) is a distressing symptom that follows cancer treatment; however, it has rarely been studied in hormone-naïve prostate cancer survivors after radical prostatectomy (RP) or definitive radiotherapy (RAD). We investigated CF in prostate cancer survivors after RP or RAD as monotherapy and explored asso...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2009.61
更新日期：2010-06-01 00:00:00
abstract：BACKGROUD:The European Organization for Research and Treatment of Cancer (EORTC) trial 22,911 reported 74% 5-year biochemical disease-free survival (bDFS) in patients with prostate carcinoma treated with radical prostatectomy (RP) followed by postoperative radiotherapy (RT). This study aimed to improve these outcomes b...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/s41391-018-0064-7
更新日期：2018-11-01 00:00:00
abstract：:Recently, studies have investigated the significance of the Wnt/β-catenin pathway in prostate cancer. The transcriptional activity of the androgen receptor (AR) is modulated by interaction with coregulators, one of which is β-catenin. Curcumin, a dietary yellow pigment of Curcuma longa, has emerged as having a chemopr...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2010.26
更新日期：2010-12-01 00:00:00
abstract：:This session included five presentations in the areas of pathology of precursor lesions and carcinoma of the prostate, the value of determining neovascularity in the diagnosis and staging of prostate cancer, new 'molecular' markers, correlation between pre- and postoperative Gleason scores and a study dealing with tra...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500277
更新日期：1999-01-01 00:00:00
abstract：:Functional expression of voltage-gated sodium channel alpha-subunits (VGSCalphas), specifically Nav1.7, is associated with strong metastatic potential in prostate cancer (CaP) in vitro. Furthermore, VGSC activity in vitro directly potentiates processes integral to metastasis. To investigate VGSCalpha expression in CaP...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500796
更新日期：2005-01-01 00:00:00
abstract：INTRODUCTION:Approximately 85% of patients who die from prostate cancer present the spread of bone metastases. Even though the radiological appearance of such metastases is osteoblastic, it is now known that these lesions coexist in their microenvironment with blastic and lytic lesions. The process always begins with b...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500752
更新日期：2004-01-01 00:00:00
abstract：BACKGROUND:To assess the added value of biopsy factors, like maximum cancer length in a core (MCL), cumulative cancer length (CCL), cumulative length of positive cores (CLPC), percentage of cancer involvement in positive cores (CIPC) and the Prostate Cancer Research International: Active Surveillance (PRIAS) criteria i...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2015.26
更新日期：2015-12-01 00:00:00
abstract：:The molecular mechanisms for hormone-resistant prostate cancer progression still remain elusive, mainly due to the limited availability of corresponding tissue. As transurethral resection (TUR) is a common palliative therapy for patients with hormone refractory prostate cancer (HRPC) who have subvesical obstruction, w...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4501001
更新日期：2008-01-01 00:00:00
